Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C

Takehide Ogihara, Hideki Katagiri, Tetsuya Yamada, Hirohito Kudo, Junta Imai, Yasushi Ishigaki, Yoshinori Hinokio, Yoko Yamagiwa, Yoshiyuki Ueno, Tooru Shimosegawa, Yoshitomo Oka

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Interferon (IFN) therapies, including IFN, peginterferon (PEG-IFN) and ribavirin (RBV) plus PEG-IFN combination, are widely used for patients with chronic hepatitis C. We encountered a patient with chronic hepatitis C in whom previous IFN or PEG-IFN alone had not induced type 1 diabetes (T1D), while the addition of RBV to PEG-IFN did induce T1D. The patient had HLA types conferring highly susceptibility to T1D. Thus, adding RBV to PEG-IFN may render chronic hepatitis C patients, with T1D-susceptible HLA types, more prone to developing T1D than IFN or PEG-IFN alone. To prevent T1D development, we recommend HLA typing prior to initiating RBV plus PEG-IFN administration.

Original languageEnglish
Pages (from-to)1387-1390
Number of pages4
JournalInternal Medicine
Volume48
Issue number16
DOIs
Publication statusPublished - 2009

Keywords

  • Anti-glutamate acid decarboxylase (GAD) antibody
  • Anti-insulinoma-associated antigen (IA)-2 antibody
  • Autoimmune disease
  • Human leukocyte antigen

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Peginterferon (PEG-IFN) plus ribavirin combination therapy, but neither interferon nor PGE-IFN alone, induced type 1 diabetes in a patient with chronic hepatitis C'. Together they form a unique fingerprint.

Cite this